Loading…
Employees: 1,748
Size Zeria Pharmaceutical (4559.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $540M, the 1023rd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,021 on 6 Nov 2026.
Performance Over six months the shares fell 6.4%, against -13.9% for the median peer and +1.8% for the Japan market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 11.6% over the last twelve months (peer median +7.9%); the operating margin is 15.2% (peer median 8.4%).
Valuation It trades at 9.3× forward earnings against a peer median of 20.6× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥94.7B | ¥89.2B | ¥87.3B | ¥75.7B | ¥68.4B |
| Revenue growth | — | +2% | +15% | +11% | — |
| Gross profit | ¥68.6B | ¥59.4B | ¥58.1B | ¥50.2B | ¥45.1B |
| EBITDA | ¥22.8B | ¥19.7B | ¥19.8B | ¥17.3B | ¥15.2B |
| Net income | ¥10.7B | ¥8.45B | ¥9.94B | ¥7.73B | ¥6.20B |
| Free cash flow | n/a | ¥7.59B | ¥11.5B | ¥9.28B | ¥10.8B |
| Capital expenditure | n/a | ¥2.90B | ¥2.73B | ¥3.90B | ¥2.66B |
| Total debt | ¥37.0B | ¥40.4B | ¥42.4B | ¥47.6B | ¥50.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4559.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.6% | -11.6% | 5th highest of 21 |
| 6-month return | -6.4% | -13.9% | 10th highest of 21 |
| Distance from 52-week high | -17.0% | -31.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +11.6% | +7.9% | 8th highest of 21 |
| Operating margin | 15.2% | 8.4% | 7th highest of 19 |
| Forward P/E | 9.3× | 20.6× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -12.5% | 6.7% | least demanding of 8 |
| Growth delivered (Del g) | +11.1% | +9.1% | 3rd highest of 8 |
| Hurdle (Req g minus delivered) | -23.6 pp | -11.5 pp | 2nd least demanding of 8 |
| ROIC minus cost of capital | +3.4 pp | -2.8 pp | 7th highest of 20 |
| EV / EBITDA | 4.1× | 24.4× | cheapest of 5 |
| Net debt / EBITDA | 0.3× | 1.5× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 9.3× | -12.5% | +11.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | n/a | -5.2% | +9.6% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | n/a | -3.9% | +7.6% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | n/a | 17.7% | +4.4% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 11.1× | -8.9% | +12.6% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 75.5× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 14.9× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | n/a | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 21.6× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | n/a | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 19.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 34.2× | n/a | n/a |